Scott M. Pittman is Director & 10% Owner at Nuo Therapeutics, Inc. (AURX). They have made 2 open-market trades across 2 companies since 2016, most recently 2026-06-30.
CIK 0001674752
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $1.4M since 2016, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AURX | 5,400,396 | — |
| PrivateUnlisted | 890,800 | — |
| Total | $0 |
Shares reported on the most recent Form 4, priced at the 2026-07-02 close. 2 holdings could not be priced and are excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AURX | BUY | 2017-08-10 | 2017-08-14 | $0.30 | $607K | N/A | N/A | N/A |
| PrivateNuo Therapeutics, Inc. | BUY | 2016-05-05 | 2016-07-29 | $1.00 | $825K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.